EUCTR2021-002126-24-BG进行中（未招募）1 期
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 522
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
- •2.Subject or legally acceptable representative must possess an educational level and degree of understanding of English or the local language that enables them to communicate suitably with the Investigator and the study coordinator.
- •3.Subject is 18 to 65 years of age, inclusive, at the time of informed consent.
- •4.Subject meets DSM-5 criteria, based on the SCID-5-CT, for bipolar I disorder, current episode depressed with or without rapid cycling disease course (= 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) with or without psychotic features.
- •5.Subject has a lifetime history of at least 1 manic episode or manic episode with mixed features corroborated by at least one of the following: medical records, documented correspondence with a treating psychiatrist or mental healthcare provider/staff, or information from a reliable informant who is familiar with the subject's psychiatric history. The adequacy of the information will be assessed by the Sponsor Eligibility Committee.
- •6. Attempts should be made to obtain supporting information regarding the subject's current major depressive episode from additional sources. This may include relevant medical records and/or documented correspondence with a treating psychiatrist or mental healthcare provider/staff if the subject has been evaluated during the current MDD episode, or information from a reliable informant who is familiar with the subject's recent psychiatric history.
- •7.Subject’s current major depressive episode is = 4 weeks and less than 12 months in duration at Screening.
- •8.Subject has a MADRS-S total score = 22 at Screening.
- •9.Subjecthas a MADRS total score = 22 at both Screening and Baseline.
- •10.Subject has a CGI-BP-S depression score = 4 at both Screening and Baseline.
- •11.Subject has a YMRS total score = 12 at both Screening and Baseline.
- •Please refer to Protocol for the complete list.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 522
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject currently has any DSM-5 defined psychiatric diagnosis other than bipolar I disorder that was the primary focus of treatment or is currently being treated with concomitant medication.
- •2.Subject has a lifetime history of, or symptoms consistent with, schizophrenia, schizoaffective disorder, or a major psychiatric diagnosis other than bipolar I disorder that is judged to pose risk to the study scientific objectives based on the judgement of the Investigator or the Sponsor Eligibility Committee. A lifetime history of anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) are not exclusionary if the disorder does not meet
- •Exclusion Criterion 1.(Note: Subjects with a previous diagnosis of major depressive disorder or bipolar II disorder that was subsequently changed to bipolar I disorder are allowed.)
- •3.Subject has a history within the past 12 months prior to Screening of substance use disorder.
- •4.Subject has confirmed or suspected borderline personality disorder.
- •5.Subject demonstrates a decrease (improvement) of = 25% in MADRS total score from Screening to Baseline.
- •6.Subject is considered by the Investigator to be at imminent risk of suicide or injury to self or others, or has a score = 4 on MADRS item 10 (suicidal ideation) or answers yes” to suicidal ideation” item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at the Screening Visit (in the past 3 months [90 days]) or at Baseline.
- •7.Subject has received any psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer) prior to Baseline or anticipates the need for psychotropic medications or herbal supplements during participation in this study, with the exception of the medications specified in Protocol Section 10.3. The following treatments have additional restrictions as specified below:
- •a.Monoamine oxidase inhibitors (MAOIs) must be discontinued at least 28 days prior to Baseline.
- •b.Fluoxetine, and olanzapine/fluoxetine combination must be discontinued at least 28 days prior to Baseline.
- •c.Clozapine used at 200 mg/day or less for insomnia, agitation, or anxiety must be discontinued at least 28 days prior to Baseline. Subjects with a history of treatment with clozapine for any reason at doses greater than 200 mg/day or at doses less than or equal to 200 mg/day for a usage other than insomnia, agitation, or anxiety are excluded from study participation.
- •d.Depot neuroleptics must have been discontinued at least one treatment cycle or at least 30 days (whichever is longer) prior to Baseline.
- •e.Subjects with a history of treatment with ketamine, esketamine, arketamine, or psychedelic therapies (eg, psilocybin, methylenedioxymethamphetamine [MDMA]) for MDD or any psychedelic
- •f.Electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) within 90 days prior to Baseline.
- •g.Subjects with a history of treatment with vagus nerve stimulation (VNS) or deep brain stimulation (DBS) are excluded from study participation.
- •8.Subject initiated a new psychotherapeutic intervention (eg, psychotherapy) focused on treatment of bipolar I depression within the past 12 weeks prior to Screening. (Note: Subjects who have participated in ongoing psychotherapy treatment for at least 12 weeks prior to Screening will be permitted to continue this treatment d
研究者
相似试验
进行中（未招募）
1 期
Research study to evaluate the effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I Disorder.Major Depressive Episode Associated with Bipolar I DisorderMedDRA version: 20.0Level: PTClassification code 10004939Term: Bipolar I disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-002126-24-SKSunovion Pharmaceuticals Inc.522
进行中（未招募）
3 期
A clinical study of an investigational drug for the treatment of Major Depressive Episode Associated with Bipolar I Disordermajor depressive episodes associated with bipolar I disorderJPRN-jRCT2031210559Yabuuchi Kazuki522
进行中（未招募）
1 期
Research study to evaluate the effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I Disorder.EUCTR2021-002126-24-HRSunovion Pharmaceuticals Inc.522
进行中（未招募）
1 期
A Study of the Effects of Atrasentan (ABT-627) on Renal Outcomes in Subjects with Type 2 Diabetes and NephropathyMedDRA version: 20.0Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersDiabetic NephropathyEUCTR2012-005848-21-DKAbbVie Deutschland GmbH & Co. KG5,500
进行中（未招募）
1 期
A Study of the Effects of Atrasentan (ABT-627) on Renal Outcomes in Subjects with Type 2 Diabetes and NephropathyMedDRA version: 20.0 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersDiabetic NephropathyEUCTR2012-005848-21-CZAbbVie Deutschland GmbH & Co. KG5,107